

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021935-000110US
Client Reference No.: SD-98-095-2



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 12/23/03

TOWNSEND and TOWNSEND and CREW LLP

By: Camela Skelton

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Judith A. VARNER

Application No.: 09/307,223

Filed: May 7, 1999

For: METHODS FOR DETECTING
AND INHIBITING ANGIOGENESIS

Examiner: S. Ungar

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references, including full copies of Guo et al. and Scott et al. as previously cited by the Examiner, are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

01/06/2004 CCHAU1 00000088 201430 09307223

01 FC:1806 180.00 DA

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Kawai Lau
Reg. No. 44,461

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 858-350-6100
Fax: 415-576-0300
KL/tp



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/307,223		
		Filing Date	May 7, 1999		
		First Named Inventor	Varner, Judith A.		
		Art Unit	1642		
		Examiner Name	S. Ungar		
Sheet	1	of	1	Attorney Docket Number	021935-000110US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC	Guo, Neng-hua, et al., "Thrombospondin 1 and Type I Repeat Peptides of Thrombospondin 1 Specifically Induce Apoptosis of Endothelial Cells", <i>Cancer Res.</i> , (1997), 57: 1735-1742	
	BD	Kim, Semi, et al., "Regulation of Angiogenesis <i>in Vivo</i> by Ligation of Integrin $\alpha_5\beta_1$ with the Central Cell-Binding Domain of Fibronectin", <i>American Journal of Pathology</i> , (2000), 156(4): 1345-1362	
	BE	Ruoslahti, Erkki, "Integrin Signaling and Matrix Assembly", <i>Tumor Biology</i> , (1996) 17(2):117-124	
	BF	Scott, Glynis, et al, "Fibronectin Suppresses Apoptosis in Normal Human Melanocytes Through an Integrin-Dependent Mechanism", <i>J. Invest. Dermatol.</i> , (1997) 108:147-153	
	BG	Yano, Yoshiko, et al, "Cyclic Strain Induces Reorganization of Integrin $\alpha_5\beta_1$ and $\alpha_2\beta_1$ in Human Vein Endothelial Cells", <i>Journal of Cellular Biochemistry</i> , (1997) 64(3):505-513	
	BH	Zhang, Zhuohua, et al. "The $\alpha_5\beta_1$ integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression", <i>Proc. Natl. Acad. Sci USA</i> , (1995) 92:6161-6165	
	BI		
	BJ		
	BK		
	BL		
	BM		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.